Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma

12 Nov 2024

Abstract excerpt

BACKGROUND: Patients with metastatic hepatoblastoma are treated with severely toxic first-line chemotherapies in combination with surgery. Yet, inadequate response of lung metastases to neo-adjuvant chemotherapy still compromises patient outcomes making new treatment strategies, tailored to more efficient lung clearance, mandatory. METHODS: We harnessed a comprehensive patient-derived xenograft platform and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Histone Deacetylase Inhibitors Research
Share to Protein Tyrosine Phosphatases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39529166
DOI: 10.1186/s13046-024-03221-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastomaPMID 39529166Read ↗

Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological responseSemantic proximity Read ↗

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunitiesSemantic proximity Read ↗

Molecular Profiling and High-Content Drug Screening of Metastatic Colorectal Cancer Organoids Reveal Evolutionary Mechanisms of Pan-KRAS Inhibitor ResistanceSemantic proximity Read ↗

Genome-wide mapping of oncogenic pathways and genetic modifiers of chemotherapy using a high-risk hepatoblastoma genetic modelSemantic proximity Read ↗

Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastomaSemantic proximity Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.Semantic proximity Read ↗

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.Semantic proximity Read ↗

Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneitySemantic proximity Read ↗

Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactionsSemantic proximity Read ↗

Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer TherapySemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.